Search

Search Constraints

You searched for: Author/Creator Metzenmacher, Martin

Search Results

1. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. (March 2021)

2. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. (May 2021)

3. Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation. (January 2020)

4. Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve. (October 2020)

5. Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy. Issue 3 (31st March 2021)

6. Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy. Issue 3 (31st March 2021)

7. ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer. (November 2020)

8. KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). (April 2021)

9. Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. (November 2020)

10. Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry. Issue 2 (2nd February 2023)